A Case of Severe Cholestatic Hepatitis Induced by a Novel Dual Agonist of Glucagon-like Peptide-1 and Glucosedependent Insulinotropic Polypeptide Receptors  

作　　者：Junmin Jiang Meifeng Shi Shuduo Wu Minling Cao 

机构地区：[1]Department of Hepatology,The Second Affiliated Hospital of Guangzhou University of Chinese Medicine,Guangzhou,Guangdong,China

出　　处：《Journal of Clinical and Translational Hepatology》2024年第11期949-954,共6页临床与转化肝病杂志（英文版）

摘　　要：Glucagon-like peptide-1(GLP-1)and glucose-dependent insulinotropic polypeptide(GIP)receptor agonists are increasingly used in the management of type 2 diabetes mellitus and obesity due to their ability to stimulate insulin secretion,delay gastric emptying,and suppress appetite.The combination of GLP-1 and GIP agonists improves glycemic control and promotes weight loss.However,the introduction of these novel therapies has raised safety concerns,including the risk of cholestatic hepatitis.We report a case of a patient with obesity who was prescribed a GLP-1/GIP dual-receptor agonist as part of his treatment regimen.Importantly,both before the initiation of this therapy and during the course of treatment,the patient was not taking any other medications.Shortly after receiving four doses of the therapy,the patient developed symptoms of severe cholestatic hepatitis,including jaundice and elevated liver enzyme levels.During hospitalization,no alternative causes for the condition were identified,and a liver biopsy confirmed the diagnosis of druginduced cholestatic hepatitis.This is the first recorded case of cholestatic hepatitis induced by a GLP-1/GIP dual agonist,and it aimed to raise global awareness of this potential side effect.

关 键 词：GLP-1 receptor GIP receptor Cholestatic hepatitis OBESITY 

分 类 号：R575.1[医药卫生—消化系统]